NCT04949516

Mono Antiplatelet and Colchicine Therapy

Aspirin-free Therapy After Successful Percutaneous Coronary Intervention for Acute Coronary Syndrome: the MACT (Mono Antiplatelet and Colchicine Therapy) Pilot Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Wonkwang University Hospital · Academic / Other
• Sex: All
• Age: 19 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of aspirin-free, P2Y12 inhibitor single antiplatelet and colchicine treatment in patients with acute coronary syndrome treated with drug-eluting stents.

Detailed description

After successful drug-eluting stent implantation for acute coronary syndrome, screening for study subject enrollment is performed. For those who submitted written informed consent, aspirin is stopped the day after the intervention, and colchicine 0.6mg once daily is started. The P2Y12 inhibitor, prasugrel or ticagrelor, for single antiplatelet therapy remains. For the duration of hospital stay, platelet reactivity using VerifyNow test and C-reactive protein are measured. Aspirin may be restarted at the discretion of the investigator based on results of the platelet function test. C-reactive protein is remeasured 30 days after the intervention. Clinical follow-up is performed 30 days and 90 days after the intervention.

Conditions

• Acute Coronary Syndrome
• Drug-Eluting Stents

Interventions

Type	Name	Description
DRUG	Aspirin	Aspirin is discontinued the day after drug-eluting stent implantation
DRUG	Colchicine	Colchicine is started the day after drug-eluting stent implantation

Timeline

• Start date: 2021-06-15
• Primary completion: 2022-12-31
• Completion: 2022-12-31
• First posted: 2021-07-02
• Last updated: 2023-01-04

Locations

1 site across 1 country: South Korea